The United States Food and Drug Administration (USFDA) conducted a pre-approval inspection (PAl) of company’s Halol facility from June 3 to June 11, 2019, Sun Pharma said in a filing to the BSE.
Sun Pharma gets 4 observations from USFDA for its Halol facility
More from Industry NewsMore posts in Industry News »
- India tops the chart for approved biosimilars and clinical trials surpassing USA and Europe: 10th Annual Pharma IPR India Conference
- India initiates antidumping probe on certain type of steel from Brazil, China, Germany
- BDR Pharma receives DGCI nod for its generic drug BIAPENEM
- AstraZeneca invests in Imperial’s self-amplifying RNA technology with eye on future drugs